Please to e a plus sign (+) inside this box

Signature

TRANSMITTAL

PTO/SB/21 (98-00)

Approval for use through 10/31/2002. OMB 0651-0031

10/016,985

12/07/01

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

Application Numb r

Filing Date

number.

		FORM			First Nan	ned Invento	r	Walke	CEP	JAN	Ö
					Group Art	Unit		1645	TEA	ಲ ಗ	四
(to b	e used for a	Il correspondence a	fter initia	al filing)	Examiner	Name		To be assigned'	58	200	H
Т	otal Number	of Pages in This Su	ubmissio	on 12	Attorney [Docket Num	ber	LEX-0273-USA) 229 0	<u> </u>	U
			EN	ICLOSUR	ES (chec	k all that ap	ply)				
_ F	ee Transmi	ital Form		Assignmei (for an Ap _i	nt Papers			After Allowance C to Group	ommuni	cation	
[Fee At	tached		Drawing(s)			Appeal Communic of Appeals and In			
	Amendment	'Reply		Licensing-	related Paper	s		Appeal Communio (Appeal Notice, Brief,			
[After F	inal		Petition				Proprietary Inform	nation		
[Affida	rits/declaration(s)			Convert to a I Application			Status Letter			
	Extension of	Time Request			Attorney, Revo		X	Other Enclosure(s identify below):	s) (pleas	e	
□ □	Express Aba	ndonment Request		Terminal [Disclaimer		F	return postcard PTO Form 1449 and		nces	
	Supplementa Disclosure St	I Information atement		Request fo	or Refund		l l	nternational Search F	Report		
	Certified Cop	•		CD, Numb	er of CD(s) _						
	Response to ncomplete A	Missing Parts/ pplication	Rer	narks							
ſ	Respo	nse to Missing Parts									
L	under	37 CFR 1.52 or 1.53				24 PATENT TR	123				
		SIG	NATII	RE OF AP	PLICANT A	TTORNEY,					
Firm		<u> </u>			,,,,	,					
<i>or</i> Individ	ual name	Lance K. Ishimo Lexicon Genetic		Reg. No. 41 porated	1,866	_					
Signati	ure	inkly to	> My	, Vily	(S) .	Ley No 40	Sese lbz	ran			
Date		January 27, 200	3 /								
				CERT	IFICATE O	F MAILING					
mail in a		this correspondence addressed to: Comm						vice with sufficient po on, VA January 27		first cla	ass
Typed o	r printed na	na Nancy Stacey									

Burden Hour Statement: This form is estimated to the 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

Date

January 27, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke et al.

Application No.: 10/016,985

Filed: 12/07/01

Title: Novel Human Kinase and

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0273-USA

Group Art Unit: 1645

Examiner: To Be Assigned:

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

<u>X</u>	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
_	under 37 CFR 1.97(c) together with either a: Certification under 37 CFR 1.97(e), or a \$180.00 fee under 37 CFR 1.17(p), or (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
	under 37 CFR 1.97(d) together with a: Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Supplemental Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

January 27, 2003

Date

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

(281) 863-3333

24231

_	PTO/SB/08A (10-96)
	Approved for use through 10/31/99. OMB 0651-0031
a	demark Office; U.S. DEPARTMENT OF COMMERCE
-2-	displays a valid OMR control number

		us sign (+) inside this box - work Reduction Act of 1995		ons are required to resp	Patent a	Approved for use ademark Office; U.	S DEPARTS	31/99. ON	B/08A (10-9) MB 0651-003 COMMERC	31
	~ ~ ~	for form 1449A/PTO				Complete if Know				
JAN 3	0 2003)			Application Numb r	10/016,985	品		71	
	3	/ SUPPLEM			Filing Date	12/07/01	_오_		<u>m</u> _	
TA TRA	INES	RMATION D	ISC	LOSURE	First Nam d Invent r	Walke	0	두		_
TRA					Group Art Unit	1645	_ 写_	Z		
	SIAI	EMENT BY	<u>API</u>	PLICANI	Examiner Name	To be assigned	===	ಲು	111	
	Sheet	1	f	2	Attorney Docket Number	LEX-0273-USA	罗		Z	

				U.S. PATENT DOCUMEN	TS	
	0	U.S. Patent	Document		Date of Publication	Page Solumns, Lines,
xaminer nitials*	Cite No.¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	of cited Document MM-DD-YYYY	Viber Relevant Passages or Relevant Figures Appear
	СК	5,985,635		Bandman et al.	11/16/99	
					<u> </u>	
		1				
		<u> </u>				
						1
		<u> </u>				
					 	
						•
					+	

				FORE	IGN PATENT DOCUMENTS	3		
Examiner	Cite		Foreign Patent Docu		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office	e³ Number⁴	Kind Code⁵ (<i>if known</i>)	Applicant of Cited Document	cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
	CL	wo	01/38503	A2	Sugen Inc.	05/31/01		
	СМ	wo	01/88148	A2	Applera Corporation	11/22/01		
	CN	wo	02/10401	A2	Millennium Pharmaceuticals	02/07/02		
	co	JP	2000 060571		Mitsubishi Chemicals	02/29/00	Abstract	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

oox —

Approved for use through 10/31/99. OMB 0651-0031
Payand Trademark Office: U.S. DEPARTMENT OF COMMERCE

~	Indies Ved	aperwork Reduction Act of 1	995, no	persons are required to	respond to a collection of information	Pale and Trademark Office; U. unless it displays a valid OMB of	S. DEPARTM control number	ENT OF C	COMMI
•		for form 1449B/PTO				Complete if Known	EC		A
JAN	3 0 ₂₀₀₃	SUPPLEM	EN.	ΤΔΙ	Application Number	10/016,985	2	F	
	2000	MATION D		LOCUEE	Filing Date	12/07/01	THE STREET	Z	
	INFC	MINITION	150	LOSURE	First Named Inventor	Walke	= = = = = = = = = = = = = = = = = = = =	E 2	<u></u>
· A	STA	PEMENT BY	API	PLICANT	Group Art Unit	1645			_<
					Examiner Name	To be assigned		<u>'è</u>	
	Sheet	2	of	2	Attorney Docket Number	LEX-0273-USA	$\underline{\underline{g}}$	<u>ن</u> ا ي	, t

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	СР	Database EMBL 'Online' EM_RO, 01/08/99, retrieved from EBI Database accession no. AB010154, XP002222847, abstract	Γ
	CQ	Database EMBL 'Online', Swall, 05/01/99, retrieved from EBI Database accession no. Q9Z335, XP002222848, abstract	Г
	CR	Scott et al., "Serine/threonine protein kinases," Current Opinion in Neurobiology, England, June 1992, Vol. 2, No. 3, pgs. 289-295, XP001131989, ISSN: 0959-4388	
		International Search Report, International Application No. PCT/US01/48533, 12/07/01 (Attorney Docket No. LEX-0273-PCT)	
			\vdash
			\vdash
			\vdash
			\vdash
i			⊬
			1

nature Considered	Examiner	Date

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.